

Pharmacy and Therapeutics Committee Meeting Record

Date: 7/16/04 **Time:** 9:00 a.m. – 3:00 p.m. **Location:** 3232 Elder Street, Conference Room D **Moderator:** Thomas R. Young, M.D.

Committee Members Present: Thomas R. Young, M.D.; Richard Pines, D.O.; Catherine Gundlach, PharmD; Jeffery Edwards, M.D.; Richard Markuson, RPh; Bob Comstock, RPh; Rick Sutton, RPh; Cynthia Bunde, P.A.; Shawna Kittridge, MHS, RPh; Steve Montamat, M.D.

Committee Members Absent: George Pfoertner, M.D.; Thomas Rau, M.D.

| Agenda Item | Presenter | Outcome/Action | Assigned | Due |
|---|------------------------------|---|----------|-----|
| <p>CALL TO ORDER</p> <ul style="list-style-type: none"> • Roll Call • Reading of Confidentiality Statement • Approval of Minutes from May 21, 2004 and June 18, 2004 Meetings • Review of SmartPA Criteria Review for Long Acting Opioids and Urinary Incontinence Classes | <p>Thomas R. Young, M.D.</p> | <p>Dr. Young informally called the roll.</p> <p>The confidentiality statement was read by Dr. Young.</p> <p>The minutes from the May 21, 2004, and June 18, 2004, Committee meeting were approved.</p> <p>Dr. Eide presented the SmartPA criteria for long-acting opioids and urinary incontinence classes.</p> <p><u>Long-Acting Opioids</u> If there is no change to current patients’ use of a non-preferred agent, the savings would be \$4,000 per quarter; however, if all patients are switched to a preferred agent, the savings would be \$257,000 per quarter. The Committee recommends that current patients’ not be grandfathered. The Committee also recommends that providers be informed and educated 60 days and again 30 days in advance of the change to allow providers and pharmacists to talk to their patients, as well as the Pharmacy Unit. Shawna will summarize this decision and send it out to the Committee members in the next two weeks.</p> <p>The Committee is concerned with the amount of time a patient would be expected to try one of the preferred agents before switching back to a non-preferred. The Committee would like the DUR Board to monitor switch rates and report back to the Committee at the time of the LAO outcome study.</p> | | |

| Agenda Item | Presenter | Outcome/Action | Assigned | Due |
|--|---|---|----------|-----|
| <ul style="list-style-type: none"> • Key Question Review – Antiplatelet Drugs • EPAP Implementation Update <ul style="list-style-type: none"> → Statin Update → ARB & BB Moved to September P&T Meeting | | <p><u>Urinary Incontinence</u> The Committee agrees with the information provider and would like the Department to proceed.</p> <p>The key questions for antiplatelet drugs were reviewed and the Committee had no changes.</p> <p>Implementation of the Statin changes will be August 1. The information on the ARBs and Beta Blockers will be discussed at the September Committee meeting.</p> | | |
| <p>CEBP DRUG EFFECTIVENESS PROJECT OVERVIEW</p> <ul style="list-style-type: none"> • History • Current Status • Next Steps | John Santa, M.D. | Dr. Santa explained the Center for Evidence-Based Policy’s objectives and the process for completing reviews. The list of drug classes that have been reviewed to date was presented to Committee members, as well as the list of drug classes to be reviewed by CEBP in the near future. | | |
| DUR UPDATE | Chris Owens, Pharm.D. | Dr. Owens presented their proposal for DUR-conducted outcome studies including what will be reviewed. He also presented the results of the outcome studies that have been completed to date. | | |
| PUBLIC COMMENT PERIOD | Thomas R. Young, M.D. | There were no people listed to speak during the public comment period. | | |
| EPAP PROJECTED SAVINGS AND MARKET SHIFT REVIEW | Shawna Kittridge, MHS, RPh and John Snow, CPA | Shawna presented the EPAP trends for the first year of the Committee. This included a review of the projected savings and market shift. | | |
| ADJOURN COMMITTEE MEETING | Thomas R. Young, M.D. | The next groups of drugs to be reviewed by the Committee will ARBs and Beta Blockers. The next Committee meeting will be September 17, 2004. | | |